title: Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
abstract: Potent and safe vaccinia virus vectors inducing cell-mediated immunity are needed for clinical use. Replicating vaccinia viruses generally induce strong cell-mediated immunity; however, they may have severe adverse effects. As a vector for clinical use, we assessed the defective vaccinia virus system, in which deletion of an essential gene blocks viral replication, resulting in an infectious virus that does not multiply in the host. The vaccinia virus Lister/Elstree strain, used during worldwide smallpox eradication, was chosen as the parental virus. The immunogenicity and safety of the defective vaccinia virus Lister were evaluated without and with the inserted human p53 gene as a model and compared to parallel constructs based on modified vaccinia virus Ankara (MVA), the present "gold standard" of recombinant vaccinia viruses in clinical development. The defective viruses induced an efficient Th1-type immune response. Antibody and cytotoxic-T-cell responses were comparable to those induced by MVA. Safety of the defective Lister constructs could be demonstrated in vitro in cell culture as well as in vivo in immunodeficient SCID mice. Similar to MVA, the defective viruses were tolerated at doses four orders of magnitude higher than those of the wild-type Lister strain. While current nonreplicating vectors are produced mainly in primary chicken cells, defective vaccinia virus is produced in a permanent safety-tested cell line. Vaccines based on this system have the additional advantage of enhanced product safety. Therefore, a vector system was made which promises to be a valuable tool not only for immunotherapy for diseases such as cancer, human immunodeficiency virus infection, or malaria but also as a basis for a safer smallpox vaccine.
authors.affiliation: Biomedical Research Center, Baxter BioScience/Vaccine AG, A-2304 Orth/Donau, Austria.
authors.forename: B T
authors.initials: BT
authors.lastname: Ober
authors.forename: P
authors.initials: P
authors.lastname: Brühl
authors.forename: M
authors.initials: M
authors.lastname: Schmidt
authors.forename: V
authors.initials: V
authors.lastname: Wieser
authors.forename: W
authors.initials: W
authors.lastname: Gritschenberger
authors.forename: S
authors.initials: S
authors.lastname: Coulibaly
authors.forename: H
authors.initials: H
authors.lastname: Savidis-Dacho
authors.forename: M
authors.initials: M
authors.lastname: Gerencer
authors.forename: F G
authors.initials: FG
authors.lastname: Falkner
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002460:Cell Line; D003588:Cytopathogenic Effect, Viral; D003673:Defective Viruses / Q000235:genetics / Q000276:immunology*; D005822:Genetic Vectors; D006801:Humans; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D011817:Rabbits; D011995:Recombination, Genetic; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000009:adverse effects* / Q000235:genetics / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000009:adverse effects* / Q000235:genetics / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D016159:Tumor Suppressor Protein p53; D014614:Vaccines, Synthetic; D014765:Viral Vaccines